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Compound 10b was introduced as a potent c-Met kinase inhibitor with IC50 of 4.6 nM and was more 
cytotoxic than crizotinib on HepG2 cells. 
 
Aim: Mesenchymal-epithelial transition factor HGF/c-Met overactivation is involved in diverse human 
cancers. Herein, we report the synthesis and biological evaluation of thiomethylpyridine-linked 
triazolotriazines as c-Met kinase inhibitors.  
Results: Compounds 10b and 11e were more potent than crizotinib on HepG2 cells with IC50 values of 
0.74 and 0.71 µM in the MTT assay, respectively. Interestingly, all of the target compounds displayed 
IC50 values in the range of 3.9-11.1 nM in the c-Met kinase inhibition assay which were lower than the 
value for crizotinib (11.1 nM).  
Conclusion: Target compound 10b can be considered as a leading drug candidate due to its lower IC50 
values than crizotinib in both HGF-induced proliferation and c-Met kinase inhibition assays.  





Mesenchymal-epithelial transition factor (c-Met) pertaining to receptor tyrosine kinases is a cell-surface 
receptor for hepatocyte growth factor (HGF). c-Met is widely distributed in the brain, human liver, 
gastrointestinal tract, and kidney. c-Met signaling leads to cell proliferation, migration, survival and 
embryonic morphogenesis [1]. HGF/c-Met over-activation is involved in diverse human tumors, such as 
glioblastomas, various carcinomas in breast, lung, liver and prostate, and in ovarian cancer [2]. Different 
strategies have been employed to regulate HGF/c-Met signaling pathway using  HGF antagonists, c-Met 
monoclonal antibodies, anti-HGF antibodies and small-molecule c-Met inhibitors [3]. Small-molecule c-
Met inhibitors, on the basis of their binding modes, have been subdivided into three types, type I, II and 
III. Type I inhibitors occupy the ATP binding pocket in the form of a “U” conformation and display high 
selectivity on the c-Met enzyme. Type II inhibitors have extended conformation in the ATP binding 
pocket of c-Met and do not have selectivity over the c-MET enzyme [4, 5]. SGX-523 (Figure 1), a type I 
and selective c-MET inhibitor has showed excellent antitumor activity on the U87MG xenograft model 
[6]. Based on previous reports, triazolotriazines bearing 4-hydroxyphenylmethyl at the 3-position and O-
linked triazolotriazines demonstrated superior c-met inhibitory activity (Figure 1, compounds 1 and 2) 
[7]. In the same compounds, the presence of a hydrogen-bond acceptor atom like nitrogen in the quinoline 
motif (Figure 1) was proved to constitute a crucial hydrogen bond with NH atom of Met1160 in the hinge 
binding region of the c-Met active site [8]. With respect to the importance of the electron-deficient 
triazolotriazine core in the formation of a strong π-π stacking interaction with Tyr-1230 in the c-Met 
activation loop, which confers potency and selectivity for c-Met inhibition against a wide range of 
kinases, we designed and synthesized the 6-aryl-triazolotriazines, 10a-f and 11a-f (Figure 1), linked 
through thiomethylene to a 3- or 4-pyridyl ring. The flexible thiomethylene side chain containing the 
pyridine motif as a hinge binder ensures the formation of an essential hydrogen bond with Met1160. The 
effect of introducing the new thiomethylene linker to attach the hinge binder pyridine ring to the 
triazolotriazine core has been investigated for c-Met kinase inhibition and cell proliferation assays. 
The chemical structure of synthesized titled compounds was confirmed by X-ray diffraction, 1H and 13C-
NMR, as well as Mass spectrometry. The anticancer activity of the target compounds was evaluated by 
HGF-induced proliferation assay against A549, HepG2, MCF7 and MDA-MB231 cell lines and 
compared to crizotinib as a selective c-MET inhibitor. The extent of cytotoxicity and apoptosis mediated 
by Caspase 3/7 activity were assessed and finally, the ability of the target compounds to inhibit c-Met 
kinase was evaluated and expressed as enzyme percent inhibition. 
 
Figure 1. Schematic representation of designed triazolotriazines 10a-f and 11a-f, based on the previous c-
Met inhibitors. 
Experimental section 
Material & Methods 
All chemical reagents and solvents were purchased from Sigma–Aldrich or Merck suppliers and 
used without further purification. Crizotinib and HGF were purchased from Sigma. The progress 
of reactions was checked by Thin-layer chromatography (TLC) using TLC Silica gel 60 F254 
(Merck, Darmstadt, Germany). A UV cabinet with wavelengths 254 and 360 nm was used for 
visualizing spots on the TLC plates. Column chromatography was performed using Silica gel 60 
(0.040-0.063 mm), Merck, Germany. Melting points were measured in open capillaries on a 
Stuart Scientific apparatus and are uncorrected. IR spectra were recorded on a FT-IR Perkin 
Elmer spectrophotometer. NMR spectra were recorded on Bruker 500 MHz spectrometer and 
tetramethylsilane (TMS) was used as the standard and chemical shifts are expressed in ppm 
units. Coupling constants are reported in Hertz (Hz). Low resolution mass spectra were measured 
using a HP 5975 Mass Selective Detector (Agilent technologies). Elemental analyses for C, H 
and N were performed by using a CHN elemental analyzer (GmbH-Germany), and the results are 
within ±0.4% of the theoretical values. 
 
Preparation of methyl hydrazinecarbimidothioate hydroiodide.  
A mixture of thiosemicarbazide (1 mmol) and iodomethane (10 mmol) in absolute ethanol were 
heated at 50C for 3h. After cooling to r.t. a white precipitate was filtrated and air dried. Yield: 
64%. m.p. 138C. 
General procedure for the preparation of 2,2-dihydroxy-1-arylethanones 4a-f 
To a suspension of SeO2 (1 equiv.) in a mixture of 1,4-dioxane and H2O (21:1) was added 
acetophenones 3a-f (1 equiv.) which was then heated at reflux for 2h. The reaction mixture was 
cooled to room temperature and filtered through Celite. The filtrate was concentrated in vacuo, 
water was added and then heated at reflux for 5h. Next, the reaction mixture was cooled in an ice 
bath to begin precipitation. The white precipitate obtained was filtered and dried in an oven.  
2,2-Dihydroxy-1-phenylethanone (4a). Yield: 57%. White powder. m.p. 83-85C. IR (KBr, cm-
1): 3405 (O-H), 1697 (C=O). 
2,2-Dihydroxy-1-(p-tolyl)ethanone (4b). Yield: 55%. White powder. m.p. 113-115C. IR (KBr, 
cm-1): 3399 (O-H), 2915 (aliphatic C-H), 1687 (C=O). 1H NMR (500 MHz, CDCl3) δ: 2.47 (s, 
3H), 7.34 (d, J = 8.2 Hz, 2H), 8.13 (d, J = 8.3 Hz, 2H), 9.68 (s, 1H). 
2,2-Dihydroxy-1-(4-methoxyphenyl)ethanone (4c). Yield: 56%. White powder. m.p. 111-114C. 
IR (KBr, cm-1): 3419 (O-H), 2987, 2944, 2846 (aliphatic C-H), 1682 (C=O).  
2,2-Dihydroxy-1-(4-hydroxyphenyl)ethanone (4d). Yield: 50%. White powder. m.p. 114-116C. 
1-(4-Bromophenyl)-2,2-dihydroxyethanone (4e). Yield: 41%. White powder. m.p. 131-133C. IR 
(KBr, cm-1): 3378 (O-H), 2974 (aliphatic C-H), 1695 (C=O). 1H NMR (500 MHz, CDCl3) δ: 
3.99 (s, 2H), 5.93 (s, 1H), 7.70 (d, J = 8.3 Hz, 2H), 8.11 (d, J = 8.4 Hz, 2H), 9.65 (s, 1H). 
1-(4-Chlorophenyl)-2,2-dihydroxyethanone (4f). Yield: 35%. White powder. m.p. 96-98C. IR 
(KBr, cm-1): 3374 (O-H), 2978 (aliphatic C-H), 1697 (C=O). 1H NMR (500 MHz, CDCl3) δ: 
7.51 (d, J = 8.3 Hz, 2H), 8.18 (d, J = 7.7 Hz, 2H), 9.64 (s, 1H). 
General procedure for the preparation of 2,2-diethoxy-1-arylethanones 5a-f 
To a solution of 2,2-dihydroxy-1-arylethanones, 4a-f (1 equiv.) in dichloromethane, p-
toluenesulfonic acid (PTSA, 0.05 equiv.) and triethyl orthoformate (2 equiv.) were added and 
heated at reflux for 2h. The solvent was removed under reduced pressure and the residue was 
chromatographed on silica gel (230–400 mesh) using chloroform as eluent.  
2,2-Diethoxy-1-phenylethanone (5a). Yield: 90%. Yellow oil. IR (KBr, cm-1): 3068 (aromatic C-
H), 2979, 2932, 2882 (aliphatic C-H), 1689 (C=O). 1H NMR (500 MHz, CDCl3) δ: 1.26 (t, J = 
7.0 Hz, 6H), 3.64-3.70 (m, 2H), 3.75-3.81 (m, 2H), 5.30 (s, 1H), 7.45-7.49 (m, 2H), 7.75-7.60 
(m, 1H), 8.17-8.19 (m, 2H). 
2,2-Diethoxy-1-(p-tolyl)ethanone (5b). Yield: 80%. Yellow oil. 1H NMR (500 MHz, CDCl3) δ: 
1.26 (t, J = 7.0 Hz, 6H), 2.42 (s, 3H), 3.63-3.70 (m, 2H), 3.73-3.80 (m, 2H), 5.29 (s, 1H), 7.27 (d, 
J = 8.1 Hz, 2H), 8.08 (d, J = 8.2 Hz, 2H). 
2,2-Diethoxy-1-(4-methoxyphenyl)ethanone (5c). Yield: 91%. Yellow oil. 1H NMR (500 MHz, 
CDCl3) δ: 1.25 (t, J = 7.0, 6H), 3.62-3.68 (m, 2H), 3.73-3.80 (m, 2H), 3.88 (s, 3H), 5.25 (s, 1H), 
6.94 (d, J = 9 Hz, 2H), 8.17 (d, J = 8.9 Hz, 2H). 
2,2-Diethoxy-1-(4-hydroxyphenyl)ethanone (5d). Yield: 90%. Pale yellow oil. The title 
compound 5d was purified by column chromatography, eluting with 5% ethylacetate in 
chloroform. 1H NMR (500 MHz, CDCl3) δ: 1.25 (t, J = 7.0 Hz, 6H), 3.64-3.70 (m, 2H), 3.72-
3.78 (m, 2H), 5.33 (s, 1H), 6.93 (d, J = 8.8 Hz, 2H), 8.12 (d, J = 8.8 Hz, 2H). 
1-(4-Bromophenyl)-2,2-diethoxyethanone (5e). Yield: 88%. Pale yellow oil. IR (KBr, cm-1): 
2978, 2931, 2882 (aliphatic C-H), 1693 (C=O). 1H NMR (500 MHz, CDCl3) δ: 1.10 (t, J = 6.9 
Hz, 6H), 3.47-3.52 (m, 2H), 3.61-3.65 (m, 2H), 5.04 (s, 1H), 7.43 (d, J = 7.9 Hz, 2H) , 7.92 (d, J 
= 7.2 Hz, 2H). 
1-(4-Chlorophenyl)-2,2-diethoxyethanone (5f). Yield: 85%. Pale yellow oil. . IR (KBr, cm-1): 
3441 (aromatic C-H), 2979, 2931, 2896 (aliphatic C-H), 1693 (C=O). 
General procedure for the preparation of 3-(methylthio)-6-aryl-1,2,4-triazines 6a-f. 
To a solution of 2,2-diethoxy-1-arylethanones, 5a-c and 5e-f (1 equiv.) in absolute ethanol were 
added PTSA (0.05 equiv.) and thiosemicarbazide (1 equiv.) and stirred at r.t. for 8h. The 
completion of the reaction was monitored by TLC. After completion, 1.1 equiv. of methyl iodide 
was added to the mixture and stirring was continued overnight. The solvent was removed under 
reduced pressure and acetic acid was added to the obtained residue and heated at 60 C overnight 
with stirring. Finally, the resulting solution was concentrated in vacuo and the crude product was 
purified by column chromatography (silica gel, 230–400 mesh) eluting with chloroform.  
3-(Methylthio)-6-phenyl-1,2,4-triazine (6a). Yield: 50%. Brown powder. m.p. 93-95C. 1H NMR 
(500 MHz, CDCl3) δ: 2.82 (s, 3H), 7.61-7.65 (m, 3H), 8.12-8.14 (m, 2H), 8.87 (s, 1H); MS: 
(m/z, %): 203.1 (M+, 30), 175.1 (10), 102.2 (100), 76.1 (25). 
3-(Methylthio)-6-(p-tolyl)-1,2,4-triazine (6b). Yield: 30%. Brown powder. m.p. 119-120C. 1H 
NMR (500 MHz, CDCl3) δ: 2.46 (s, 3H), 2.74 (s, 3H), 7.37 (d, J = 8 Hz, 2H), 7.96 (d, J = 8.2 
Hz, 2H), 8.77 (s, 1H); MS: (m/z, %): 217.2 (M+, 31), 116.2 (100), 89.1 (14). 
6-(4-Methoxyphenyl)-3-(methylthio)-1,2,4-triazine (6c). Yield: 40%. Brown powder. m.p. 140-
143C. 1H NMR (500 MHz, CDCl3) δ: 2.74 (s, 3H), 3.90 (s, 3H), 7.07 (d, J = 8.9 Hz, 2H), 8.02 
(d, J = 8.8 Hz, 2H), 8.75 (s, 1H); MS: (m/z, %): 233.1 (M+, 82), 132.2 (100), 117.1 (74), 89.1 
(66). 
4-(3-(Methylthio)-1,2,4-triazin-6-yl)phenol (6d). Yield: 41%. To a suspension of 2,2-diethoxy-1-
(4-hydroxyphenyl)ethanone, 5d (1 equiv.) in absolute ethanol, PTSA (0.05 equiv.) and methyl 
hydrazinecarbimidothioate hydroiodide (1 equiv.) were added and stirred at r.t. for 8h. The 
solution was concentrated under vacuum, then acetic acid was added and heated at 60 C 
overnight with stirring. The crude product was purified on a silica gel column, eluting with 5% 
ethylacetate in chloroform to give the yellow powder. m.p. 147-150C. 1H NMR (500 MHz, 
DMSO-d6) δ: 2.65 (s, 3H), 6.94 (d, J = 8.7 Hz, 2H), 8.01 (d, J = 8.7 Hz, 2H), 9.13 (s, 1H), 10.07 
(s, 1H); MS: (m/z, %): 219.1 (M+, 86), 118.2 (100), 89.1 (65). 
6-(4-Bromophenyl)-3-(methylthio)-1,2,4-triazine (6e). Yield: 54%. The residue was crystallized 
from ethanol to aff ord 6e as brown crystals. m.p. 157-159C. 1H NMR (500 MHz, CDCl3) δ: 
2.74 (s, 3H), 7.70 (d, J = 8.5 Hz, 2H), 7.94 (d, J = 8.5 Hz, 2H), 8.77 (s, 1H); MS: (m/z, %): 281.0 
(M+, 19), 283.1 (M+2, 19), 180.1 (100), 101.1 (57). 
6-(4-Chlorophenyl)-3-(methylthio)-1,2,4-triazine (6f). Yield: 37%. Brown powder. m.p. 155-
157C. 1H NMR (500 MHz, CDCl3) δ: 2.74 (s, 3H), 7.53 (d, J = 8.6 Hz, 2H), 8.01 (d, J = 8.6 Hz, 
2H), 8.77 (s, 1H); MS: (m/z, %): 237.1 (M+, 20), 239.1 (M+2, 7.7), 136.2 (100), 101.1 (29). 
General procedure for the preparation of 3-(methylsulfonyl)-6-aryl-1,2,4-triazines 7a-f 
To a suspension of 3-(methylthio)-6-aryl-1,2,4-triazines, 6a-f (1 equiv.) in THF was added 
potassium peroxymonosulfate (oxone®, 1 equiv.) in water, and mixture was stirred at r.t. for 2h 
(water/THF, 1:1, v/v). After completion of the reaction, it was partially concentrated in vacuo to 
50% volume. The precipitate was filtered and washed with water and dried in oven. The crude 
product was crystallized from ethanol to afford light yellow crystals.  
3-(Methylsulfonyl)-6-phenyl-1,2,4-triazine (7a). Yield: 66%. m.p. 180-183C. IR (KBr, cm-1): 
3461, 3058 (aromatic C-H), 2916 (aliphatic C-H), 1598, 1537 (S=O). 1H NMR (500 MHz, 
CDCl3) δ: 3.15 (s, 3H), 7.63-7.64 (m, 3H), 8.16-8.18 (m, 2H), 9.20 (s, 1H); MS: (m/z, %): 235.1 
(M+, 2), 219.1 (14), 128.1 (73), 102.1 (100), 77.1 (40).   
3-(Methylsulfonyl)-6-(p-tolyl)-1,2,4-triazine (7b). Yield: 43%. m.p. 200-202C. IR (KBr, cm-1): 
3399, 3065, 3002 (aromatic C-H), 2919 (aliphatic C-H), 1607, 1554 (S=O). 1H NMR (500 MHz, 
CDCl3) δ: 2.48 (s, 3H), 3.13 (s, 3H), 7.42 (d, J = 8.0 Hz, 2H), 8.07 (d, J = 8.2 Hz, 2H), 9.16 (s, 
1H); MS: (m/z, %): 249.1 (M+, 2), 237.1 (10), 190.1 (11), 136.0 (100), 116.1 (100).  
6-(4-Methoxyphenyl)-3-(methylsulfonyl)-1,2,4-triazine (7c). Yield: 83%. m.p. 144-145C. IR 
(KBr, cm-1): 3451, 3000 (aromatic C-H), 2967, 2931, 2838 (aliphatic C-H), 1605, 1578 (S=O). 
1H NMR (500 MHz, CDCl3) δ: 3.13 (s, 3H), 3.94 (s, 3H), 7.13 (d, J = 8.9 Hz, 2H), 8.16 (d, J = 
8.9 Hz, 2H), 9.14 (s, 1H); MS: (m/z, %): 265.1 (M+, 2), 249.1 (12), 174.1 (20), 158.1 (59), 132.1 
(100). 
4-(3-(Methylsulfonyl)-1,2,4-triazin-6-yl)phenol (7d). Yield: 60%. m.p. 195-197C. 1H NMR (500 
MHz, DMSO-d6) δ: 3.01 (s, 3H), 7.00 (d, J = 8.7 Hz, 2H), 8.16 (d, J = 8.7 Hz, 2H), 9.52 (s, 1H), 
10.30 (s, 1H); MS: (m/z, %): 251.9 (M+, 2), 179.9 (26), 132.1 (33), 93.0 (49), 64.0 (100). 
6-(4-Bromophenyl)-3-(methylsulfonyl)-1,2,4-triazine (7e). Yield: 85%. m.p. 189-191C. IR 
(KBr, cm-1): 3459, 3085, 3047 (aromatic C-H), 1586 (S=O). 1H NMR (500 MHz, CDCl3) δ: 3.15 
(s, 3H), 7.78 (d, J = 8.6 Hz, 2H), 8.06 (d, J = 8.6 Hz, 2H), 9.18 (s, 1H); MS: (m/z, %): 313.0 
(M+, 2), 315.0 (M+2, 2), 297.0 (9), 206.0 (41), 180.1 (100), 127.1 (98), 101.1 (57). 
6-(4-Chlorophenyl)-3-(methylsulfonyl)-1,2,4-triazine (7f). Yield: 88%. m.p. 210-212C. 1H 
NMR (500 MHz, CDCl3) δ: 3.15 (s,3H), 7.61 (d, J =8.6 Hz, 2H), 8.14 (d, J =8.7 Hz, 2H), 9.18 
(s, 1H); MS: (m/z, %): 269.1 (M+, 0.5), 253.1 (8), 162.1 (46), 136.1 (100), 101.1 (19). 
General procedure for the preparation of 3-hydrazinyl-6-aryl-1,2,4-triazines 8a-f 
To a suspension of 3-(methylsulfonyl)-6-aryl-1,2,4-triazines 7a-f (1 mmol) in THF (11 ml) was 
added 0.53 ml of hydrazine monohydrate and the resulting mixture stirred at r.t. for 2h. The 
precipitated product was filtered and air dried.  
3-Hydrazinyl-6-phenyl-1,2,4-triazine (8a). Yield: 86%. Yellow powder. m.p. 192-194C. IR 
(KBr, cm-1): 3275, 3218 (N-H), 3055 (aromatic C-H), 2965 (aliphatic C-H). 1H NMR (500 MHz, 
DMSO-d6) δ: 4.46 (brs, 2H), 7.46 (t, J = 7.3 Hz, 1H), 7.52 (t, J = 7.5 Hz, 2H), 8.02 (d, J = 7.2 
Hz, 2H), 8.87 (s, 1H); MS: (m/z, %): 187.2 (M+, 80), 116 (13), 102.2 (100).  
3-Hydrazinyl-6-(p-tolyl)-1,2,4-triazine (8b). Yield: 70%. Yellow powder. m.p. 173-174C. . IR 
(KBr, cm-1): 3432, 3233 (N-H), 3043 (aromatic C-H). 1H NMR (500 MHz, DMSO-d6) δ: 2.36 (s, 
3H), 4.47 (brs, 2H), 7.32 (d, J = 8.1 Hz, 2H), 7.91 (d, J = 8.2 Hz, 2H), 8.82 (brs, 1H), 8.85 (s, 
1H); MS: (m/z, %): 201.2 (M+, 84), 130.1 (8), 116.2 (100), 89.1 (12). 
3-Hydrazinyl-6-(4-methoxyphenyl)-1,2,4-triazine (8c). Yield: 65%. Yellow powder. m.p. 213-
215C. IR (KBr, cm-1): 3461, 3254 (N-H), 3039 (aromatic C-H), 2963, 2840 (aliphatic C-H). 1H 
NMR (500 MHz, DMSO-d6) δ: 3.82 (s, 3H), 4.42 (s, 2H), 7.07 (d, J = 8.9 Hz, 2H), 7.97 (d, J = 
8.8 Hz, 2H), 8.74 (brs, 1H), 8.83 (s, 1H); MS: (m/z, %): 217.2 (M+, 72), 132.2 (100), 117.0 (38), 
89.1 (32). 
4-(3-Hydrazinyl-1,2,4-triazin-6-yl)phenol (8d). Yield: 64%. The yellow needle crystals were 
obtained by recrystallization from ethanol. m.p. 243-245C. 1H NMR (500 MHz, DMSO-d6) δ: 
4.38 (brs, 2H), 6.88 (d, J = 8.6 Hz, 2H), 7.84 (d, J = 8.6 Hz, 2H), 8.67 (brs, 1H), 8.77 (s, 1H).  
6-(4-Bromophenyl)-3-hydrazinyl-1,2,4-triazine (8e). Yield: 90%. Yellow powder. m.p. 228-
230C. IR (KBr, cm-1): 3438, 3249 (N-H). 1H NMR (500 MHz, DMSO-d6) δ: 4.48 (s, 2H), 7.71 
(d, J = 8.5 Hz, 2H), 7.98 (d, J = 8.6 Hz, 2H), 8.89 (s, 1H), 8.96 (brs, 1H); MS: (m/z, %): 265.0 
(M+, 35), 267.0 (M+2, 35), 250.0 (5), 182.0 (100), 101.0 (52). 
6-(4-Chlorophenyl)-3-hydrazinyl-1,2,4-triazine (8f). Yield: 80%. Yellow powder. m.p. 230-
232C. IR (KBr, cm-1): 3301, 3224 (N-H), 3042 (aromatic C-H), 2969 (aliphatic C-H). 1H NMR 
(500 MHz, DMSO-d6) δ: 4.48 (brs, 2H), 7.57 (d, J = 8.6 Hz, 2H), 8.05 (d, J = 8.6 Hz, 2H), 8.89 
(s, 1H), 8.95 (brs, 1H). 
General procedure for the preparation of 6-aryl-[1,2,4]triazolo[4,3-b][1,2,4]triazine-3-thiols 
9a-f 
To a suspension of 3-hydrazinyl-6-aryl-1,2,4-triazines 8a-f (1 mmol) in ethanol (15 ml), were 
added successively potassium hydroxide (2N, 1.3 ml) and carbon disulfide (1.3 ml) and the 
mixture was refluxed for 1 h. After completion, the reaction mixture was cooled to r.t. and 
concentrated in vacuo. 1 N aqueous potassium hydroxide was added to the residue, heated and 
sonicated. Then solution was filtered and the filtrate was acidified to pH 2-3 with 1 N aqueous 
HCl to precipitate the product. The resulting precipitate was filtered, washed with water and 
dried in oven. It was used in the next step without further purification.  
 6-Phenyl-[1,2,4]triazolo[4,3-b][1,2,4]triazine-3-thiol (9a). Yield: 88%. Light orange powder. 
m.p. 272-274C. 1H NMR (500 MHz, DMSO-d6) δ: 7.64-7.66 (m, 3H), 8.16-8.18 (m, 2H), 9.35 
(s, 1H), 14.94 (s, 1H); MS: (m/z, %): 229.1 (M+, 100), 197.1 (5), 116.1 (22), 104.1 (51), 89.1 
(15). 
6-(p-Tolyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazine-3-thiol (9b). Yield: 60%. Light orange powder. 
m.p. 254-257C. 1H NMR (500 MHz, DMSO-d6) δ: 2.43 (s, 3H), 7.45 (d, J = 8 Hz, 2H), 8.09 (d, 
J = 8.2 Hz, 2H), 9.34 (s, 1H), 14.88 (s, 1H); MS: (m/z, %): 243.1 (M+, 100), 229.1 (3), 155.1 
(10), 130.1 (26), 118.1 (60), 91.1 (26). 
6-(4-Methoxyphenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazine-3-thiol (9c). Yield: 82%. Light orange 
powder. m.p. 232-234C. 1H NMR (500 MHz, DMSO-d6) δ: 3.88 (s, 3H), 7.19 (d, J = 8.9 Hz, 
2H), 8.16 (d, J = 8.9 Hz, 2H), 9.34 (s, 1H), 14.84 (s, 1H). 
4-(3-Mercapto-[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl)phenol (9d). Yield: 71%. Brick red 
powder. m.p. 260-262C. 1H NMR (500 MHz, DMSO-d6) δ: 6.99 (d, J = 8.7 Hz, 2H), 8.06 (d, J 
= 8.8 Hz, 2H), 9.30 (s, 1H), 14.81 (s, 1H). 
6-(4-Bromophenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazine-3-thiol (9e). Yield: 73%. Light orange 
powder. m.p. 257-259C. 1H NMR (500 MHz, DMSO-d6) δ: 7.87 (d, J = 8.6 Hz, 2H), 8.12 (d, J 
=  8.6 Hz, 2H), 9.35 (s, 1H), 14.95 (s, 1H); MS: (m/z, %): 307.0 (M+, 8), 309 (M+2, 8), 267.0 
(100), 196 (69), 149.9 (36), 102.0 (31), 88.0 (24). 
6-(4-Chlorophenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazine-3-thiol (9f). Yield: 90%. Light orange 
powder. m.p. 247-249C. 1H NMR (500 MHz, DMSO-d6) δ: 7.73 (d, J = 8.7 Hz, 2H), 8.20 (d, J 
= 8.7 Hz, 2H), 9.35 (s, 1H), 14.95 (s, 1H); MS: (m/z, %): 263.1 (M+, 8), 219.1 (33), 168.0 (88), 
149.0 (100), 136.0 (30), 89.1 (38). 
General procedure for the preparation of final derivatives  
To a suspension of 6-aryl-[1,2,4]triazolo[4,3-b][1,2,4]triazine-3-thiols 9a-f (1 equiv.) and 1.1 
equiv. of 3- or 4-(chloromethyl)pyridine hydrochloride in DMSO, was added 2.5 equiv. of  
potassium carbonate which was then stirred at r.t. for 3h. Chloroform was added to the resulting 
mixture and washed with water (×3), then dried over Na2SO4 and concentrated to give the crude 
product as a brown oil. Final products were purified by column chromatography (silica gel, 230–
400 mesh) eluting with chloroform/methanol (1%).  
6-Phenyl-3-((pyridin-4-ylmethyl)thio)-[1,2,4]triazolo[4,3-b][1,2,4]triazine (10a) 
Yield: 30%; m.p. 130-132C. 1H NMR (500 MHz, CDCl3) δ: 4.59 (s, 2H), 7.38 (d, J = 5.9 Hz, 
2H), 7-56-7.61 (m, 3H), 7.98 (dt, J = 1.5, 6.6 Hz, 2H), 8.50 (d, J = 5.8 Hz, 2H), 8.95 (s, 1H); 13C 
NMR (125 MHz, CDCl3) δ: 34.6, 124.1, 127.6, 129.8, 131.1, 132.3, 144.8, 145.7, 146.0, 148.2, 
148.8, 150.2; MS: (m/z, %): 320.1 (M+, 92), 287.1 (9), 229.1 (100), 190.1 (31), 104.1 (64), 77.1 
(35). Anal. Calcd for C16H12N6S: C, 59.98; H, 3.78; N, 26.23. Found: C, 59.89; H, 3.83; N, 
26.29. 
3-((Pyridin-4-ylmethyl)thio)-6-(p-tolyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazine (10b) 
Yield: 35%; m.p. 187-188C. 1H NMR (500 MHz, CDCl3) δ: 2.44 (s, 3H), 4.58 (s, 2H), 7.36-
7.38 (m, 4H), 7.88 (d, J = 8.2 Hz, 2H), 8.50 (dd, J = 1.5, 6 Hz, 2H), 8.93 (s, 1H) ; 13C NMR (125 
MHz, CDCl3) δ: 21.7, 34.6, 124.1, 127.4, 128.2, 130.5, 143.1, 144.7, 145.7, 146.1, 148.2, 148.8, 
150.2; MS: (m/z, %): 334.1 (M+, 100), 301.1 (10), 256.1 (8), 224.1 (8), 190.0 (47), 116.1 (47). 
Anal. Calcd for C17H14N6S: C, 61.06; H, 4.22; N, 25.13. Found: C, 61.19; H, 4.24; N, 25.09. 
 
6-(4-Methoxyphenyl)-3-((pyridin-4-ylmethyl)thio)-[1,2,4]triazolo[4,3-b][1,2,4]triazine (10c) 
Yield: 37%; m.p. 148-150C. 1H NMR (500 MHz, CDCl3) δ: 3.88 (s, 3H), 4.56 (s, 2H), 7.05 (d, 
J = 8.9 Hz, 2H), 7.37 (d, J = 5.9 Hz, 2H), 7.94 (d, J = 8.8 Hz, 2H), 8.49 (d, J = 6 Hz, 2H), 8.91 
(s, 1H) ; 13C NMR (125 MHz, CDCl3) δ: 34.6, 55.79, 115.3, 123.3, 124.1, 129.2, 144.6, 145.8, 
146.0, 147.7, 148.8, 150.2, 163.0; MS: (m/z, %): 350.1 (M+, 100), 317.1 (8), 215.1 (23), 190.0 
(46), 146.1 (46), 132.1 (56). Anal. Calcd for C17H14N6OS: C, 58.27; H, 4.03; N, 23.98. Found: C, 
58.35; H, 4.05; N, 24.05. 
4-(3-((Pyridin-4-ylmethyl)thio)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl)phenol (10d) 
Yield: 15%; m.p. 211-213 C. 1H NMR (500 MHz, DMSO-d6) δ:  4.45 (s, 2H), 6.89 (d, J = 8.5 
Hz, 2H), 7.29 (d, J = 4.7 Hz, 2H), 7.94 (d, J = 8.6 Hz, 2H), 8.37 (brs, 2H), 9.22 (s, 1H), 10.28 (s, 
1H) ;13C NMR (125 MHz, DMSO-d6) δ: 34.5, 116.8, 122.5, 124.5, 130.1, 143.2, 147.1, 148.3, 
148.6, 149.3, 150.2, 161.6; MS: (m/z, %): 336.1 (M+, 15), 187.1 (31), 119.0 (42), 93.1 (100). 
Anal. Calcd for C16H12N6OS: C, 57.13; H, 3.60; N, 24.98. Found: C, 57.02; H, 3.66; N, 24.90. 
6-(4-Bromophenyl)-3-((pyridin-4-ylmethyl)thio)-[1,2,4]triazolo[4,3-b][1,2,4]triazine (10e) 
Yield: 30%; m.p. 158-160C. 1H NMR (500 MHz, CDCl3) δ: 4.53 (s, 2H), 7.32 (d, J = 5.6 Hz, 
2H), 7.66 (d, J = 8.3 Hz, 2H), 7.81 (d, J = 8.3 Hz, 2H), 8.44 (d, J = 5.4 Hz, 2H), 8.85 (s, 1H); 13C 
NMR (125 MHz, CDCl3) δ: 34.5, 124.1, 127.4, 128.9, 129.9, 133.1, 145.0, 145.4, 145.6, 147.3, 
148.6, 150.2; MS: (m/z, %): 398 (M+, 58), 400 (M+2, 60), 367.0 (9), 334.1 (22), 215.1 (18), 
190.0 (100), 92.1 (73). Anal. Calcd for C16H11BrN6S: C, 48.13; H, 2.78; N, 21.05. Found: C, 
48.22; H, 2.71; N, 21.12. 
6-(4-Chlorophenyl)-3-((pyridin-4-ylmethyl)thio)-[1,2,4]triazolo[4,3-b][1,2,4]triazine (10f) 
Yield: 20%; m.p. 151-153 C. 1H NMR (500 MHz, CDCl3) δ:  4.54 (s, 2H), 7.33 (d, J = 4.9 Hz, 
2H), 7.51 (d, J = 8.4 Hz, 2H), 7.88 (d, J = 8.4 Hz, 2H), 8.45 (d, J = 4.9 Hz, 2H), 8.68 (s, 1H); 
MS: (m/z, %): 354.1 (M+, 100), 356.1 (M+2, 39), 321.1 (22), 263.0 (58), 190.0 (85), 163.0 (27), 
136.0 (85), 92.1 (77). Anal. Calcd for C16H11ClN6S: C, 54.16; H, 3.13; N, 23.69. Found: C, 
54.25; H, 3.18; N, 23.61. 
6-Phenyl-3-((pyridin-3-ylmethyl)thio)-[1,2,4]triazolo[4,3-b][1,2,4]triazine (11a) 
Yield: 38%; m.p. 145-147 C. 1H NMR (500 MHz, CDCl3) δ: 4.62 (s, 2H), 7.20 (dd, J = 4.8, 7.8 
Hz, 1H), 7.56-7.61 (m, 3H), 7.82 (dt, J = 1.9, 7.8 Hz, 1H), 7.98 (dt, J = 1.7, 6.5 Hz, 2H), 8.46 
(dd, J = 1.5, 4.7 Hz, 1H), 8.66 (d, J = 2.0 Hz, 1H), 8.95 (s, 1H) ; 13C NMR (125 MHz, CDCl3) δ: 
33.2, 123.6, 127.6, 129.8, 131.1, 132.3, 132.6, 136.9, 145.0, 146.0, 148.2, 148.7, 149.3,150.3; 
MS: (m/z, %):  320.2 (M+, 18), 287.1 (20), 242.1 (8), 190.1 (56), 116.1 (29), 92.1 (100). Anal. 
Calcd for C16H12N6S: C, 59.98; H, 3.78; N, 26.23. Found: C, 60.09; H, 3.84; N, 26.16. 
3-((Pyridin-3-ylmethyl)thio)-6-(p-tolyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazine (11b) 
Yield: 30%; m.p. 173-175C. 1H NMR (500 MHz, CDCl3) δ: 2.43 (s, 3H), 4.60 (s, 2H), 7.18 (dd, 
J = 4.8, 7.8 Hz, 1H), 7.34 (d, J = 8.0 Hz, 2H), 7.80 (dt, J = 1.8, 7.8 Hz, 1H), 7.86 (d, J = 8.2 Hz, 
2H), 8.44 (d, J = 4.5 Hz, 1H), 8.64 (s, 1H), 8.92 (s, 1H) ; 13C NMR (125 MHz, CDCl3) δ: 21.7, 
33.2, 123.6, 127.4, 128.2, 130.5, 132.6, 136.9, 143.1, 144.9, 146.1, 148.1, 148.8, 149.2, 150.3; 
MS: (m/z, %): 334.1 (M+, 36), 301.1 (29), 256.1 (12), 215.1 (15), 190.0 (73), 130.1 (35), 116.1 
(62), 92.1 (100). Anal. Calcd for C17H14N6S: C, 61.06; H, 4.22; N, 25.13. Found: C, 61.14; H, 
4.16; N, 25.06. 
6-(4-Methoxyphenyl)-3-((pyridin-3-ylmethyl)thio)-[1,2,4]triazolo[4,3-b][1,2,4]triazine (11c) 
Yield: 34%; m.p. 146-148C. 1H NMR (500 MHz, CDCl3) δ: 3.87 (s, 3H), 4.59 (s, 2H), 7.03 (d, 
J = 8.8 Hz, 2H), 7.18 (dd, J = 4.8, 7.7 Hz, 1H), 7.80 (d, J = 7.8 Hz, 1H), 7.93 (dd, J = 1.8, 8.8 
Hz, 2H), 8.43 (d, J = 4.7 Hz, 1H), 8.63 (s, 1H), 8.91 (s, 1H) ; 13C NMR (125 MHz, CDCl3) δ: 
33.2,  55.7, 115.2, 123.3, 123.6, 129.2, 132.6, 136.9, 144.7, 146.0, 147.7, 148.7, 149.2, 150.3, 
163.0; MS: (m/z, %): 350.1 (M+, 42), 317.1 (23), 272.1 (12), 190.0 (62), 132.1 (75), 92.1 (100). 
Anal. Calcd for C17H14N6OS: C, 58.27; H, 4.03; N, 23.98. Found: C, 58.32; H, 4.08; N, 23.90. 
4-(3-((Pyridin-3-ylmethyl)thio)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl)phenol (11d) 
Yield: 25%; m.p. 268-270C. 1H NMR (500 MHz, DMSO-d6) δ: 4.61 (s, 2H), 7.02 (d, J = 8.7 
Hz, 2H), 7.33 (dd, J = 4.7, 7.7 Hz, 1H), 7.83 (dd, J = 1.5, 7.8 Hz, 1H), 8.07 (d, J = 8.7 Hz, 2H), 
8.44 (d, J = 4 Hz, 1H), 8.59 (s, 1H), 9.33 (s, 1H) ; 13C NMR (125 MHz, CDCl3) δ: 32.5, 116.2, 
121.8, 123.3, 129.4, 133.3, 136.4, 142.8, 147.7, 147.8, 148.4, 148.6, 149.8, 161.0; MS: (m/z, %): 
336.1 (M+, 2), 292.1 (9),174.1 (27), 119.0 (88), 92.1 (100). Anal. Calcd for C16H12N6OS: C, 
57.13; H, 3.60; N, 24.98. Found: C, 57.18; H, 3.56; N, 24.92. 
6-(4-Bromophenyl)-3-((pyridin-3-ylmethyl)thio)-[1,2,4]triazolo[4,3-b][1,2,4]triazine (11e) 
Yield: 37%; m.p. 176-178C. 1H NMR (500 MHz, CDCl3) δ: 4.63 (s,2H), 7.21 (dd, J = 4.8, 7.8 
Hz, 1H), 7.72 (d, J = 8.6 Hz, 2H), 7.82 (dt, J = 1.9, 7.8 Hz, 1H), 7.87 (d, J = 8.6 Hz, 2H), 8.46 
(dd, J = 1.5, 4.8 Hz, 1H), 8.67 (d, J = 2.1 Hz, 1H), 8.91 (s, 1H) ; 13C NMR (125 MHz, CDCl3) δ: 
33.2, 123.6, 127.4, 128.9, 130.0, 132.5, 133.1, 136.9, 145.2, 145.4, 147.3, 148.6, 149.3, 150.3; 
MS: (m/z, %): 398 (M+, 8), 400 (M+2, 8), 365.1 (8), 281.0 (4), 215.1 (14), 190.0 (63), 92.1 
(100). Anal. Calcd for C16H11BrN6S: C, 48.13; H, 2.78; N, 21.05. Found: C, 48.10; H, 2.84; N, 
21.10. 
6-(4-Chlorophenyl)-3-((pyridin-3-ylmethyl)thio)-[1,2,4]triazolo[4,3-b][1,2,4]triazine (11f) 
Yield: 40%; m.p. 158-160C. 1H NMR (500 MHz, CDCl3) δ: 4.62 (s, 2H), 7.20 (dd, J = 4.9, 7.7 
Hz, 1H), 7.55 (d, J = 8.6 Hz, 2H), 7.81 (dt, J = 1.8, 7.9 Hz, 1H), 7.94 (d, J = 8.6 Hz, 2H), 8.46 
(d, J = 4.6 Hz, 1H), 8.66 (s, 1H), 8.91 (s, 1H) ; 13C NMR (125 MHz, CDCl3) δ: 33.2, 123.6, 
128.8, 129.5, 130.1, 132.5, 136.9, 138.9, 145.2, 145.4, 147.2, 148.6, 149.3, 150.3; MS: (m/z, %): 
354 (M+, 12), 356 (M+2, 4), 321.1 (12), 240.0 (13), 215.1 (22), 190.1 (46), 92.1 (100). Anal. 
Calcd for C16H11ClN6S: C, 54.16; H, 3.13; N, 23.69. Found: C, 54.19; H, 3.17; N, 23.77. 
X-ray crystallography 
A crystal of compound 11c was prepared by slow evaporation in acetonitrile and mounted under 
Paratone-N oil and flash cooled to 150 K in a stream of nitrogen in an Oxford Cryostream cooler. 
Single-crystal X-ray intensity data (Table 1) were collected using an Agilent Gemini S Ultra 
diffractometer (Cu Kα radiation (λ = 1.54180 Å)). The data were reduced within the CrysAlisPro 
software. [9] The structure was solved using the program Superflip [10] and all non-hydrogen 
atoms located. Least-squares refinements on F were carried out using the CRYSTALS suite of 
programs. [11] The non-hydrogen atoms were refined anisotropically. All hydrogen atoms were 
located using difference Fourier maps. Each hydrogen atom connected to carbon was placed 
geometrically with a C-H distance of 0.95 Å and a Uiso of 1.2 times the value of Uequiv of the 
parent C atom. The positions of these hydrogen atoms were then refined with riding constraints. 
[12]  
 
HGF-induced proliferation assay 
The anti-proliferative activities of compounds and positive control crizotinib (Sigma, PZ0191) 
were evaluated against MCF-7, MDA-MB-231, HepG2 and A549 cell lines using MTT assay. 
The cancer cell lines were cultured in Dulbecco’s modified eagle’s medium (DMEM) 
supplemented with 10% FBS, %1 L-glutamine and % 0.5 antibiotics at 37 °C in a humidified 
atmosphere containing 5% CO2. Cancer cells were seeded in 96-well plates at 5000 cells/well. 
After 24 hours’ incubation, cells were starved in FBS-free medium containing 0.1% BSA and 
recombinant human HGF (40 ng/ml) (Sigma, H5791) for 24 h, then treated with test compounds 
at different concentrations for 72 hours at 37 °C. After incubation, 10 µL MTT reagent (5 
mg/ml) was added to each well. MTT formazan crystals were dissolved by the addition of 100 
µL DMSO. Relative cell viability was estimated by comparing the absorbance values at 690 nm 
(for absorbance of MTT formazan) and 570nm (for the reference wavelength) of the treated 
group and untreated control group using a Biotek Power Wave XS microplate reader. IC50 values 
were calculated using GraphPad Prism software. [13, 14] 
 
Caspase 3/7 Activity Assay 
MCF-7, MDA-MB-231, HepG2 and A549 cells were seeded at a density of 1 x 103 cells per well 
in Lumox (Sarstedt) 384-well plates. After cells were challenged with recombinant human HGF 
(40 ng/ml) (Sigma, H5791) for 24 h, the test compounds were added at 20 µM concentration and 
the cells were incubated for an additional 24 hours at 37°C. The ApoTox-Glo Triplex Assay 
(Promega, USA) was performed to estimate viability, cytotoxicity and caspase-3/7 activity 
following the manufacturer’s instructions. Briefly 5 µL viability/cytotoxicity reagent were added 
to the wells and after 1 hour of incubation at 37°C, viability (400ex/505em) and cytotoxicity 
(485ex/520em) were measured. Later 25 µL Caspase-Glo reagent was added to the wells and the 
plate is incubated for an hour at room temperature. Luminescence was measured using a 
multimode plate reader (BMG Labtech Omega FLUOstar). Caspase 3/7 activity results were 
normalized well-to-well by the ratio of the number of live cells to the number of dead cells. [15] 
 
c-Met inhibition assay 
Met Kinase Enzyme System (V3361, Promega, USA) with ADP-Glo assay was used for the c-
Met inhibition assay. It was performed in duplicate to screen kinase inhibitory activities of 
compounds at 20 µM, 5 µM, 0,5 µM, 0.05 µM and 0.5 nM concentrations according to the 
manufacturer’s instructions. Briefly reactions were set up in 384-well Lumox (Sarstedt) plates 
containing kinase buffer, 10 μM ATP, 0.2 µg/µl poly (Glu, Tyr) 4:1 peptide substrate and 8 ng c-
Met kinase for 1 hour at room tempature. ADP formed from kinase reactions were measured by 
ADP-Glo kinase assay. 5 μL of ADP-Glo™ reagent was added to the wells to stop the kinase 
reaction and plate is incubated for 40 min at room temperature. After adding 10 μL of kinase 
detection reagent and 30 min of additional incubation; luminescence was measured using a 
multimode plate reader (BMG Labtech Omega FLUOstar). The percentage of inhibition (I%) 
was estimated by comparing the kinase activities of samples to vehicle. IC50 values of the 
compounds were determined from percent kinase inhibition values between 20 µM-0.5 nM 
compound concentrations using Graphpad Prism 5 software. 
  
Molecular docking study 
A docking study was performed employing the AutoDock 4.2 software with the AutoDock Tools 
(ADT) interface. Compounds 10c and 11c were docked into the binding site of c-met tyrosine 
kinase (PDB code: 3ZXZ). At first, for the preparation of protein, all the water and ligands were 
removed and the protein structure was optimized and the Kollman charge was computed. The 
compound’s structure was then optimized and Gasteiger–Huckel charges were added. The 
Lamarckian genetic algorithm was utilized for the docking search. A grid box was generated by 
Autogrid 4.2. Autogrid and autodock files were created by the following parameters: Grid center: 
X = 19.775, Y = 83.506, Z = 4.432, Grid spacing = 0.375, number of points: 60 × 60 × 60, 
number of evaluations: 2,500,000, population size: 150, GA run: 30. 
 
Results & Discussion 
Chemistry 
The synthetic procedure for the title compounds is depicted in Figure 3. Oxidation of 
acetophenones (3a-f) by using selenium dioxide in a mixture of 1,4-dioxane and water in 
refluxing mode afforded corresponding 2,2-dihydroxy-1-arylethanones (4a-f) [16]. Subsequently 
compounds (4a-f) were reacted with triethyl orthoformate in the presence of p-toluenesulfonic 
acid (PTSA) in dichloromethane under reflux to give corresponding acetal intermediates (5a-f) 
[7]. The triazine ring closure was carried out in three successive steps for compounds 6a-c and 
6e-f. At the first step, reaction of acetal intermediates (5a-f) with thiosemicarbazide in the 
presence of PTSA in ethanol at room temperature led to the imine formation, then, methylation 
of the thiosemicarbazide thiol group was performed using iodomethane, and finally 1,2,4-triazine 
ring closure was done in acetic acid [17]. In order to prepare compound 6d, the acetal 
intermediate 5d was reacted with methyl hydrazinecarbimidothioate hydroiodide in the presence 
of PTSA in ethanol and then stirred in acetic acid at 60°C [18]. Next, the 3-methylthio group was 
oxidized by oxone in tetrahydrofuran and water at room temperature to afford 7a-f [19]. The 3-
hydrazinyl intermediates (8a-f) were prepared by replacement of the 3-methylsulfonyl group 
with a hydrazine group [17] and eventually it was cyclized in the presence of carbon disulfide in 
ethanol to give 3-mercapto-[1,2,4]triazolo[4,3-b][1,2,4]triazines 9a-f [20]. Final products, 10a-f 
and 11a-f, were prepared by adding commercially available 3- or 4-(chloromethyl)pyridine 
hydrochloride to 3-mercapto-1,2,4-triazolo-1,2,4-triazines 9a-f in dry DMSO and potassium 
carbonate [21]. Exploring 1H NMR spectra of compounds 10a-f and 11a-f (NMR spectra in 
Supplementary material) shows that aliphatic SCH2 protons appeared as singlet and are located 
at 4.45-4.59 and 4.59-4.63 ppm respectively. Notably, a singlet appeared at 8.85-8.95 ppm for 
compounds 10a-f and 11a-f is attributed to the C7-H proton of the triazine ring (Figure 2), 
except in 10d and 11d, where the same proton has been deshielded to 9.22 and 9.33 ppm, 
respectively. The 1H-NMR spectra of compounds 10a-f show 4 doublets in the aromatic part of 
each spectrum, of which two of them belong to the para-substituted aryl ring located at position 
6 of triazolotriazine nucleus. Basically, the other two doublets in the form of an AB quartet at 7.3 
and 8.4-8.5 ppm correspond to the pyridine ring for compounds 10a-f. For example, the 
spectrum of 6-(4-bromophenyl)-3-((pyridin-4-ylmethyl)thio)-[1,2,4]triazolo[4,3-
b][1,2,4]triazine (10e) revealed two singlet signals in 8.85 and 4.53 ppm attributed to C-H in the 
triazolotriazine ring and S-CH2, respectively. The AB quartet signals at 7.32 and 8.44 ppm 
correspond to pyridine ring protons and the AB quartet signals at 7.66 and 7.81 ppm are related 
to 4-bromophenyl ring protons. 13C-NMR spectrum of 10e displayed one signal at 34.5 ppm 
referring to S-CH2, and 11 signals ranging from 124.1-150.2 ppm attributed to carbons in 
aromatic rings. 
 
Figure 2. Atom numbering of [1,2,4]triazolo[4,3-b][1,2,4]triazine nucleus in IUPAC nomenclature. 
In the 1H-NMR spectra of compounds 11a-f, the aryl ring substituted at position 6 of the 
triazolotriazine nucleus revealed two doublets in the form of an AB quartet, as observed for 
compounds 10a-f. Generally, the pyridine ring in compounds 11a-f shows a unique pattern as a 
doublet of doublets exists at 7.2 ppm, a multiplet (doublet of doublets or doublet of triplets) at 
7.8, a doublet (or a doublet of doublets) at 8.4 and a singlet (or a doublet) at 8.6 ppm, and 
correctly confirm the presence of a pyridine-3-yl substructure. Specifically, in the 1H-NMR 
spectrum of compound 11e, signals appeared at 7.73 and 7.87 ppm as a doublet corresponding to 
4-bromophenyl ring protons. Signals at 7.20 (dd), 7.81 (dt), 8.46 (dd) and 8.66 (d) are assigned 
as pyridine-3-yl protons. Thus, signals at 4.63 and 8.91 ppm are related to aliphatic SCH2 and 
triazine C7-H protons respectively. In the 13C-NMR spectrum of 11e, the aliphatic SCH2 carbon 
atom appeared at 33.23 ppm and the remaining 13 aromatic carbon atoms are located in the 
range of 123.64-150.37 ppm and certainly confirms the correct structure of this compound. 
 
Figure 3. Synthetic scheme of triazolotriazines 10a-f and 11a-f. a) 1. SeO2, 1,4-dioxane, reflux 2. H2O, 
reflux b) Triethyl orthoformate, PTSA, CH2Cl2, reflux c) compounds 6a-c and 6e-f: 1. Thiosemicarbazide, 
EtOH, PTSA, rt 2. CH3I, stirr, rt 3. AcOH, 60°C d) compound 6d: methyl hydrazinecarbimidothioate 
hydroiodide, PTSA, EtOH, rt 2. AcOH,60°C, stirr e) Oxone, THF, H2O, rt f) NH2NH2.H2O, THF, rt g) CS2, KOH, 
EtOH, reflux h) R2CH2Cl, K2CO3, DMSO, rt. 
 
In vitro stability study 
13C-NMR spectroscopy was used to evaluate the stability of compound 11d in a mixture of 
deuterated DMSO and chloroform. The solution of compound 11d was stable at room 
temperature after 4 weeks and any signs of degradation or variations in chemical shifts were not 




X-ray crystallography was performed for a crystal of compound 11c and the results are shown in 
Figure 4 and presented in Table 1. There is one molecule of 11c in the asymmetric unit, giving 
rise to four molecules in the unit cell (Figure S1 in supplementary material). The molecules pack 
together in a zig zag fashion along the c axis (Figure S2 in supplementary material). A series of 
π-π interactions between the aromatic rings in adjacent molecules serve to hold the packed 
structure together. For example, the distance of the centroid of ring C(10), C(11), C(12), C(13), 
C(14), C(15) to the plane in the adjacent molecule containing the ring N(2), N(3), N(6), C(4), 
C(5), C(7) is 3.426(2) Å, and the distance of the centroid of the ring N(2), N(3), N(6), C(4), C(5), 
C(7) to this plane is 3.276(2) Å. Also the distance of the centroid of the ring N(20), C(18), C(19), 
C(21), C(22), C(23) to the plane in the adjacent molecule containing the ring N(20), C(18), 
C(19), C(21), C(22), C(23) is 3.432(2) Å. Notably, the distance of the centroid of the ring N(2), 
N(3), N(6), C(4), C(5), C(7) to the plane in the adjacent molecule containing the ring N(2), N(8), 
N(9), C(1), C(7) is 3.245(2) Å. (Figure S3 in supplementary material) Data have been deposited 
at the Cambridge Crystallographic Data Centre, deposit code: CCDC 1853261. 
 
Figure 4. ORTEP structure of compound 11c; Asymmetric unit with labelling scheme. 
 
 
Table 1. Crystallographic data for 11c at 150 K. 
Formula C17 H14 N6 O1 S1 
Mr 350.40 
Crystal system monoclinic 







ρcalc/g cm-3 1.458 
Crystal habit yellow plate 
Crystal dimensions /mm 0.03 x 0.06 x 0.21 
Radiation Cu Kα 
T/K 150 
μ/mm-1 1.967 
No. Reflections (I ≤ 3σ(I)), 
no. parameters 
2684, 226 
R(F), Rw(F) 0.0300, 0.0399 
 
HGF-induced proliferation assay 
The inhibitory effect of compounds on HGF-induced cell proliferation was evaluated against four cancer 
cell lines, including A549, HepG2 and MCF7 as high c-Met expressing cell lines, and against MDA-MB-
231 as a low c-Met expressing cell line and the results are summarized in Table 2.  Crizotinib, as a 
selective c-Met kinase inhibitor, was used as a reference drug in this study and the cancer cells were 
treated with recombinant human Hepatocyte Growth Factor (HGF) to induce c-Met kinase expression and 
activation. As the data in Table 2 indicate, most compounds exhibited good to excellent cytotoxicity with 
IC50 values ranging from 0.71 to 24.29 µM against four cancer cells. In general, all target compounds 
were more potent against A549 and HepG2 compared to the other two cell lines, MCF7 and MDA-MB-
231. IC50 values of the target compounds on A549 range from 0.74 to 5.25 µM, but none of them showed 
more potency than the reference drug crizotinib (0.32 µM). The most potent compound on A549 cell line 
was determined to be compound 11b, with an IC50 value of 0.74 µM. Interestingly, the data on HepG2 are 
the most promising since IC50 values range from 0.71 to 3.25 µM and two of the compounds displayed 
more cytotoxicity than crizotinib. Notably, compounds 10b and 11e with IC50 values of 0.74 and 0.71 µM 
respectively on HepG2 cells, showed 2.1 and 2.2-fold more potency than crizotinib (IC50 = 1.57 µM). 
Moreover, the target compounds showed acceptable cytotoxicity on MCF7 cancer cell lines and their IC50 
values were in the range 9.46-21.17 µM. None of the target molecules were more cytotoxic than 
crizotinib (IC50 = 3.028 µM) on MCF7 cells but again compound 10b was shown to have more 
cytotoxicity than the others with an IC50 value of 9.46 µM. The target compounds exhibited mild to 
moderate potency on MDA-MB-231 as a low expressing c-Met cell line. In all, HepG2 was the most 
sensitive cancer cell line against target molecules 10a-e and 11a-e. Substituent variations on the 6-aryl 
ring by methyl, methoxy, hydroxyl, bromine and chlorine groups displayed minimal impact on the cell 
proliferation results, so that no correlation could be found to relate structure and activity of these 
compounds. This finding can also be confirmed by docking calculations, in which the 6-aryl ring is 
oriented towards the solvent accessible region and there is not any contact between groups attached to the 
6-aryl ring and the c-Met active site. There is no improvement or significant difference in the biological 
effects of the 4-pyridyl- and 3-pyridyl linked triazolotriazine compounds. On the other hand, the type of 
substitution of the pyridine ring has not changed the IC50 values on all cell lines significantly. This fact is 
clarified and discussed in the docking part of the discussion.  
 
Table 2. Structure and IC50 values of compounds 10a-f and 11a-f in HGF-induced cell proliferation assay. 
 
Compd. R1 R2                                                 IC50 (µM) 
 
 A549 HepG2 MCF7 MDA-MB-231 
 
10a H 4-pyridyl 2.020.03 1.270.02 16.431.09 9.651.15 
10b Me 4-pyridyl 1.140.09 0.740.07* 9.461.10 24.291.20 
10c MeO 4-pyridyl 5.200.05 1.100.03 9.641.06 6.091.05 
10d OH 4-pyridyl 4.680.04 1.270.02 10.071.06 11.151.06 
10e Br 4-pyridyl 5.050.04 1.270.03 10.751.07 6.361.13 
10f Cl 4-pyridyl 5.250.03 1.470.02 21.171.21 16.181.15 
11a H 3-pyridyl 3.110.04 1.110.02 19.471.10 11.161.12 
11b Me 3-pyridyl 0.740.05 1.020.03 9.761.06 11.551.06 
11c MeO 3-pyridyl 1.760.04 3.250.04 10.191.03 10.071.07 
11d OH 3-pyridyl 1.430.04 2.110.07 10.191.05 11.911.06 
11e Br 3-pyridyl 2.330.06 0.710.04* 12.551.09 11.591.07 
11f Cl 3-pyridyl 2.780.06 1.010.02 17.891.08 9.481.09 
Crizotinib   0.320.06 1.570.03 3.0281.06 1.991.08 
The data are presented as mean±SEM and each experiment was performed in triplicate. 
Bold values show the IC50 values of the target compounds lower than the values of crizotinib (also marked by an 
asterisk) or the most promising compounds in each column. 
 
Caspase 3/7 Activity Assay 
 
Caspases pertain to cysteine-aspartic proteases, promote controlled cell death or apoptosis. They 
modulate both intrinsic and extrinsic apoptotic pathways. Activation of caspases are mediated by 
proteolytic cleavage and finally leading to cell death during the apoptotic process. Impairment of 
apoptosis contribute in cancer development and progression. According to studies, the amount of 
caspases in cancer cells is reduced compared to normal cells.  
The compounds were tested at 20 µM for 24 hours for viability, cytotoxicity and caspase 3/7 activity 
which is a marker of apoptosis in MCF7, MDA-MB-231, HepG2 and A549 cells and the data are 
illustrated in Figure 5. Accordingly, the compounds showed high cytotoxicity while caspase 3/7 activity 
was decreased. These results suggest that compounds are fast acting necrotic agents within 24 h and do 
not induce apoptosis through caspase 3/7 activity. These data also confirmed the results obtained by MTT 





Figure 5. Extent of cytotoxicity and apoptosis mediated by Caspase 3/7 activity on MCF7, A549, HepG2 
and MDA-MB-231 cell lines. Target compounds were tested at 20 µM concentration. 
c-Met kinase inhibition assay 
All compounds displayed significant c-Met kinase inhibition potential which were more than the values of 
crizotinib at 5, 0.5, 0.05 µM and 0.5 nM concentrations and the data are summarized in Table 3, as 
percent inhibition of c-Met kinase activity. All compounds showed complete inhibition of c-Met kinase 
activity at 20 µM, while crizotinib has 91% inhibition of c-Met kinase activity at this concentration (data 
not shown). At 5 µM concentration, all compounds had higher than 90% inhibition of c-Met, while 
compounds 10a and 11d showed the highest percentage inhibitions of 96.8% and 97.7%, respectively, 
which is higher than crizotinib (92.0%). At 0.5 µM concentration of target compounds, the percentage 
inhibition of c-Met was evaluated to be more than 80% for all compounds and interestingly, compounds 
10a (85.9%), 10b (84.2%), 11b (84.4%), 11e (87.7%) and 11f (86.1%) were shown to be more potent 
than crizotinib (83.0%) at this concentration. Surprisingly, the evaluation of c-Met kinase activity at lower 
concentration (0.05 µM) of target compounds, showed that compounds 10a (79.3%), 10b (80.8%), 10c 
(77.6%), 10e (77.9%), 11b (80.9%), 11e (79.1%) and 11f (81.4%) have more inhibition potential of c-Met 
kinase activity than crizotinib (76.0%). Finally at 0.5 nM concentration, all the compounds exhibited a 
higher percent inhibition of c-Met kinase activity than crizotinib. Interestingly, all compounds displayed 
IC50 values in the range of 3.9-11.1 nM for c-Met kinase inhibition, clearly confirming that all compounds 
are more potent than crizotinib (IC50 = 11.1 nM).  
As the data in Table 3 indicate, inclusion of the substituted pyridine ring (3- or 4-pyridyl) has not induced 
a significant or regular difference in potency between compounds 10a-f and their equivalent derivatives 
11a-f. Correspondingly, the potency difference between the compounds is largely dependent on the type 
of substituted group at the para position of the phenyl ring. On the other hand, methyl- and bromine- 
substituted compounds 10b, 10e, 11b and 11e are the most potent ones in this series.  
The obtained results confirmed our original hypothesis about high potency of thiomethylpyridine linked 
triazolotriazines to inhibit c-Met kinase activity and successfully suggest that all compounds and 
especially 10b are recommended drug candidates for further in vivo and in vitro evaluations in the future. 
 
Table 3. Percent inhibition of c-Met kinase activity by target compounds 10a-f and 11a-f at four different 
concentrations. 
 
Compd. R1 R2 % c-Met inhibitionSEM  
IC50 (nM)    5 µM 0.5 µM 0.05 µM 0.5 nM 
10a H 4-pyridyl 96.80.9 85.93.35 79.31.7 19.01.7 6.2±0.07 
10b Me 4-pyridyl 93.91.3 84.24.62 80.81.8 23.83.6 4.6±0.10 
10c MeO 4-pyridyl 94.63.2 81.15.32 77.61.9 17.13.1 8.0±0.12 
10d OH 4-pyridyl 95.81.7 83.32.44 74.41.2 23.02.5 6.5±0.07 
10e Br 4-pyridyl 92.12.3 81.13.37 77.93.0 29.61.7 3.9±0.10 
10f Cl 4-pyridyl 93.11.9 83.51-17 74.83.4 12.12.9 11.1±0.08 
11a H 3-pyridyl 96.81.4 83.22.42 73.92.4 16.62.3 9.3±0.07 
11b Me 3-pyridyl 93.51.0 84.44.58 80.91.6 20.33.5 5.6±0.10 
11c MeO 3-pyridyl 94.41.0 80.02.84 71.73.5 23.02.9 7.8±0.09 
11d OH 3-pyridyl 97.70.8 79.52.32 75.42.8 14.61.7 10.1±0.09 
11e Br 3-pyridyl 90.21.3 87.72.02 79.13.3 18.21.0 6.4±0.08 
11f Cl 3-pyridyl 92.41.4 86.12.54 81.42.9 15.41.0 6.7±0.08 
Crizotinib   92.02.2 83.02.61 76.01.7 11.41.4 11.1±0.09 
Bold values are %inhibition values higher than the value of crizotinib. 
 
 
Molecular docking study 
To explore the binding mode of the target compounds and to reach conclusions about the 
structure-activity relationship, molecular docking was performed for the two compounds, 10c 
and 11c as 4- and 3-pyridyl-linked triazolotriazines, respectively. Accordingly, PDB code 3ZXZ 
was used for an in silico study and our docking protocol was validated by the docking of co-
crystal ligand PF-04217903 into the ATP-binding site of c-Met tyrosine kinase. The results of 
docking for the two compounds, 10c and 11c, are presented in Figure 6, and Figures S4 and S5 
in the Supplementary material. As illustrated in Figure 6, both compounds have a very similar 
binding conformation so that the two compounds are almost superimposed on each other. 
Essentially, the triazolotriazine ring forms a hydrogen bond with Asp1222 and a π-π stacking 
interaction with Tyr1230, which are important in the exquisite c-Met kinase selectivity and 
potency. The pyridyl moiety occupies the hinge region and its nitrogen atom forms a crucial 
hydrogen bond with Met1160. The presence of a hydrogen-bond acceptor atom at this region of 
inhibitor has been implied in many SAR studies of c-Met kinase inhibitors [22]. As shown in 
Figures S4 and S5, this hydrogen bond has distances of 1.94 and 1.89 Å, respectively for 
compounds 10c and 11c. Furthermore, π-π stacking interaction occurs between Tyr1230 and p-
methoxyphenyl ring. There are also several pi-alkyl interactions between bound inhibitors and 

















Figure 6. a) Binding conformation of compounds 10c (gray) and 11c (brown) in the ATP-binding site of 
c-Met kinase. b) 2D map of bound conformation of 11c in the ATP-binding site of c-Met kinase. 
 
Conclusion 
In summary, a series of compounds for use as c-Met kinase inhibitors were designed, synthesized 
and characterized by NMR, Mass spectrometry and X-ray crystallography. Their cytotoxicity 
was evaluated on A549, HepG2, MCF7 and MDA-MB-231 cancer cell lines. Most of the target 
compounds exhibited good to excellent cytotoxicity on A549 and HepG2 cell lines with IC50 
values ranging from 0.71 to 5.25 µM. Interestingly, compounds 10b and 11e displayed more 
cytotoxicity than the reference drug crizotinib on HepG2 cells with IC50 of 0.74 and 0.71 µM 
respectively. Evaluation of c-Met kinase activity of target compounds showed that all 
compounds are more potent than crizotinib with IC50 values in the range of 3.9-11.1 nM. 
Finally, compound 10b was introduced as a lead compound with IC50 value of 4.6 nM for c-Met 
kinase activity.  
Future Perspective 
Due to the emerge of new cancer types and resistance phenomenon to antitumor drugs, key 
biologic macromolecules involved in cancer progression have attracted much attention in drug 
discovery. c-Met tyrosine kinase receptor is one of the crucial targets responsible for tumor 
progression and migration and several studies have disclosed the triazolotriazines as a privileged 
scaffold for c-Met kinase inhibition. In the current study, novel triazolotriazine analogs were 
introduced as new leads for future drug development process as potent c-Met kinase inhibitors.   
Summary Points 
Design & synthesis of target compounds 
 A series of compounds were designed, synthesized and biologically evaluated as c-Met tyrosine 
kinase inhibitors. 





 Compounds 10b and 11e were more cytotoxic than crizotinib on HepG2 cells with IC50 values of 
0.74 and 0.71 µM respectively. 
 All of the compounds were more potent than crizotinib in c-Met kinase inhibition assay. 
 Compound 10b was introduced as a lead compound with IC50 of 4.6 nM for c-Met kinase. 
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